Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics.
The pharmacokinetics and toxicity of albendazole, mebendazole and praziquantel are extensively reviewed, drawing on original published work and reviews in the open scientific literature and on assessments by international agencies and official regulatory bodies in Europe and the USA. Information about human and veterinary medical uses and adverse reactions is evaluated. The totality of the non-clinical information available about these long-established drugs may not comply with current official guidelines for new medicines but reasons are given why the "deficiencies" are only apparent and the data gaps can be replaced by other results, largely obtained from the target species and the many years of clinical experience of safe use of these drugs in humans and animals.
Dayan
A D
AD
Parasitic Diseases and Vector Control (PVC), Communicable Diseases Control, Prevention and Eradication (CPE), World Health Organization, CH-1211 Geneva 27, Switzerland. engelsd@who.ch
D015766:Albendazole / Q000009:adverse effects* / Q000737:chemistry / Q000493:pharmacokinetics* / Q000633:toxicity; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D006801:Humans; D008463:Mebendazole / Q000009:adverse effects* / Q000737:chemistry / Q000493:pharmacokinetics* / Q000633:toxicity; D011223:Praziquantel / Q000009:adverse effects* / Q000737:chemistry / Q000493:pharmacokinetics* / Q000633:toxicity; D018675:Toxicity Tests
D000871:Anthelmintics; D011223:Praziquantel; D008463:Mebendazole; D015766:Albendazole